ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Anticoagulants, drugs that prevent blood clot formation, are some of the most commonly prescribed medications. These drugs reduce the risk of heart attacks and strokes but have a trade-off: They increase the risk of excessive bleeding. Physicians also administer the drugs during surgeries such as heart bypasses, where blood must flow smoothly through an artificial circuit outside the body. Excess bleeding in that situation is a thorny problem. Now, a team from Germany, Australia, and Sweden has developed an antibody that they say can stop blood clots without causing abnormal bleeding (Sci. Transl. Med. 2014, DOI: 10.1126/scitranslmed.3006804). The antibody, called 3F7, inhibits factor XIIa, a serine protease enzyme in the complex biochemical pathway that triggers clot formation. Thomas Renné of the Karolinska Institute and University Hospital, Stockholm, and colleagues tested 3F7 in rabbits. Compared with heparin, a commonly used anticoagulant, 3F7 was equally good at preventing clots and better at controlling excess bleeding.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X